Grilli A, Sciandra M, Terracciano M, Picci P, Scotlandi K
Laboratory of Experimental Oncology, CRS Development of Biomolecular Therapies, Rizzoli Orthopedic Institute, Via di Barbiano 1/10, 40136, Bologna, Italy.
PROMETEO, STB, RIT Department, Rizzoli Orthopedic Institute, Bologna, Italy.
BMC Med Genomics. 2015 Jun 30;8:34. doi: 10.1186/s12920-015-0106-0.
microRNAs (miRs) are small non-coding RNAs involved in the fine regulation of several cellular processes by inhibiting their target genes at post-transcriptional level. Osteosarcoma (OS) is a tumor thought to be related to a molecular blockade of the normal process of osteoblast differentiation. The current paper explores temporal transcriptional modifications comparing an osteosarcoma cell line, Saos-2, and clones stably transfected with CD99, a molecule which was found to drive OS cells to terminally differentiate.
Parental cell line and CD99 transfectants were cultured up to 14 days in differentiating medium. In this setting, OS cells were profiled by gene and miRNA expression arrays. Integration of gene and miRNA profiling was performed by both sequence complementarity and expression correlation. Further enrichment and network analyses were carried out to focus on the modulated pathways and on the interactions between transcriptome and miRNome. To track the temporal transcriptional modification, a PCA analysis with differentiated human MSC was performed.
We identified a strong (about 80 %) gene down-modulation where reversion towards the osteoblast-like phenotype matches significant enrichment in TGFbeta signaling players like AKT1 and SMADs. In parallel, we observed the modulation of several cancer-related microRNAs like miR-34a, miR-26b or miR-378. To decipher their impact on the modified transcriptional program in CD99 cells, we correlated gene and microRNA time-series data miR-34a, in particular, was found to regulate a distinct subnetwork of genes with respect to the rest of the other differentially expressed miRs and it appeared to be the main mediator of several TGFbeta signaling genes at initial and middle phases of differentiation. Integration studies further highlighted the involvement of TGFbeta pathway in the differentiation of OS cells towards osteoblasts and its regulation by microRNAs.
These data underline that the expression of miR-34a and down-modulation of TGFbeta signaling emerge as pivotal events to drive CD99-mediated reversal of malignancy and activation of differentiation in OS cells. Our results describe crucial and specific interacting actors providing and supporting their relevance as potential targets for therapeutic differentiative strategies.
微小RNA(miR)是一类小的非编码RNA,通过在转录后水平抑制靶基因参与多种细胞过程的精细调控。骨肉瘤(OS)是一种被认为与成骨细胞分化正常过程的分子阻滞有关的肿瘤。本文通过比较骨肉瘤细胞系Saos-2和稳定转染CD99的克隆,探索了时间转录修饰,CD99是一种被发现可驱动OS细胞终末分化的分子。
亲代细胞系和CD99转染细胞在分化培养基中培养14天。在此条件下,通过基因和miRNA表达阵列对OS细胞进行分析。通过序列互补和表达相关性对基因和miRNA分析进行整合。进行进一步的富集和网络分析以聚焦于调控的通路以及转录组和miR组之间的相互作用。为了追踪时间转录修饰,对分化的人骨髓间充质干细胞进行了主成分分析。
我们鉴定出约80%的基因强烈下调,其中向成骨样表型的逆转与TGFβ信号通路相关分子如AKT1和SMADs的显著富集相匹配。同时,我们观察到几种与癌症相关的微小RNA如miR-34a、miR-26b或miR-378的调控。为了解它们对CD99细胞中修饰的转录程序的影响,我们将基因和微小RNA时间序列数据进行关联。特别是,发现miR-34a相对于其他差异表达的miR的其余部分调控一个独特的基因子网络,并且它似乎是分化初始和中期几个TGFβ信号基因的主要调节因子。整合研究进一步强调了TGFβ通路在OS细胞向成骨细胞分化中的作用及其受微小RNA的调控。
这些数据强调,miR-34a的表达和TGFβ信号通路的下调是驱动CD99介导的OS细胞恶性逆转和分化激活的关键事件。我们的结果描述了关键且特定的相互作用因子,并支持它们作为治疗性分化策略潜在靶点的相关性。